UK generics industry: "Let's shut the stable door before the horse bolts"
This article was originally published in SRA
Executive Summary
The British Generic Manufacturers Association says it is working with the government to address long term issues affecting generics companies before they start to affect the sustainability of the industry1. Increasing pricing pressures, intellectual property rights issues and current levels of competition could all conspire to threaten the industry if action is not taken immediately, said the association at its annual general meeting.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.